The patient, the drug and the kidney

Drug and Therapeutics Bulletin

Volumn 44, Issue 12, 2006, Pages 89-95

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; ALFACALCIDOL; ALLOPURINOL; ANALGESIC AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCITRIOL; CALCIUM CHANNEL BLOCKING AGENT; CHINESE DRUG; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; CYTOTOXIC AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GENTAMICIN; HERBACEOUS AGENT; LITHIUM; LOOP DIURETIC AGENT; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VANCOMYCIN; VITAMIN D;

ACUTE KIDNEY FAILURE; CHRONIC KIDNEY DISEASE; CONTRACT; DISEASE CLASSIFICATION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG INFORMATION; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENERAL PRACTITIONER; GLOMERULUS FILTRATION RATE; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPOTENSION; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TUBULE DISORDER; MEDICAL DECISION MAKING; NATIONAL HEALTH SERVICE; NEPHROTOXICITY; OUTCOMES RESEARCH; PATIENT REFERRAL; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; REGISTER; RENOVASCULAR DISEASE; REVIEW; UNITED KINGDOM;

CHRONIC DISEASE; DRUG THERAPY; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; PHARMACOKINETICS;

EID: 33846060771     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2006.441289     Document Type: Review

References (44)

1. DH Renal NSF Team, 2005. The National Service Framework for renal services - Part Two: Chronic kidney disease, acute renal failure and end of life care [online]. Available: http://www.dh.gov.uk/assetRoot/04/10/ 26/80/04102680.pdf [Accessed 16 November 2006].
2. BMA, 2006. Quality and outcomes framework guidance: Summary of indicators - clinical domain. Chronic kidney disease [online]. Available: http://www.bma.org.uk/ap.nsf/Content/ qof06~summclinical#ChronicKidneyDisease [Accessed 16 November 2006].
3. Stevens LA et al. Assessing kidney function - measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-83.
4. MacGregor MS. The implementation of eGFR reporting. Br J Renal Med 2006; 11: 5-8.
5. Coresh J et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 2002; 39: 920-9.
6. Levey AS et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
7. Department of Health, 2006. Estimating glomerular filtration rate (eGFR): Information for General Practitioners [online]. Available: http://www.dh.gov.uk/assetRoot/04/13/30/21/04133021.pdf [Accessed 16 November 2006].
8. Joint Specialty Committee on Renal Medicine of the Royal College of Physicians of London and the Renal Association, 2006 Chronic kidney disease in adults: UK guidelines for identification, management and referral [online]. Available: http://www.renal.org/CKDguide/full/ CKDprintedfullguide.pdf [Accessed 16 November 2006].
9. National Kidney Foundation, 2002. K/DOQI Clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Executive summary [online]. Available: http://www.kidney.org/professionals/KDOQI/guidelines_ckd/p1_exec.htm [Accessed 16 November 2006].
10. Department of Health, 2004. Management of medicines: A resource to support implementation of the wider aspects of medicines management for the National Service Frameworks for Diabetes, Renal Services and Long-Term Conditions [online]. Available: http://www.dh.gov.uk/assetRoot/ 04/08/87/55/04088755.pdf [Accessed 16 November 2006].
11. de Lusignan S et al. Identifying patients with chronic kidney disease from general practice computer records. Fam Pract 2005; 22: 234-41.
12. Coresh J et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1-12.
13. Go AS et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305.
14. John R et al. Unreferred chronic kidney disease: a longitudinal study. Am J Kidney Dis 2004; 43: 825-35.
15. Bar J et al. Prediction of pregnancy outcome in subgroups of women with renal disease. Clin Nephrol 2000; 53: 437-44.
16. Davison J, Baylis C. Renal Disease. In: de Swiet M (Ed.). Medical disorders in obstetric practice. Third edition. London: Blackwell Science Ltd, 1995.
17. Corsonello A et al. Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch Intern Med 2005; 165: 790-5.
18. Ashley C, Currie A. The Renal Drug Handbook. Second Edition, Oxford: Radcliffe Press, 2004.
19. Joint Formulary Committee. British National Formulary. Edition 52. London: Royal Pharmaceutical Society of Great Britain and British Medical Association, September 2006.
20. Cassidy MJ, Kerr DN. Renal Disorders. In: Davies DM. Textbook of adverse drug reactions. Oxford: Oxford University Press, 1991.
21. Lord GM et al. Nephropathy caused by Chinese herbs in the UK. Lancet 1999; 354: 481-2.
22. Yang CS et al. Rapidly progressive fibrosing interstitial nephritis associated with Chinese herbal drugs. Am J Kidney Dis 2000; 35: 313-8.
23. Grant A et al. "Chinese herbal uropathy and nephropathy"? Lancet 2006; 368: 1416-7.
24. Loboz KK, Shenfield GM. Drug combinations and impaired renal function - the 'triple whammy'. Br J Clin Pharmacol 2005; 59: 239-43.
25. Blades S, Burden R for the Royal College of General Practitioners, 2006. Introducing eGFR. Promoting good CKD management [online]. Available: http://www.renal.org/eGFR/resources/eGFRnatInfoLflt0406.pdf [Accessed 16 November 2006].
26. Monsteller RD. Simplified calculation of body-surface area. N Engl J Med 1987; 315: 1098.
27. Failings in treatment advice, SPCs and black triangles. DTB 2001; 39: 25-7.
28. Galli G, Panzetta G. Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects? J Nephrol 2002; 15: 480-8.
29. Harris RC. Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol 2002; 89 (suppl): 10D-17D.
30. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999; 106: 13S-24S.
31. Huerta C et al. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 2005; 45: 531-9.
32. Davison AM et al. Oxford Textbook of Nephrology. Second Edition. Oxford: Oxford University Press, 1998.
33. Zhang J et al. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 2006; 296: 1619-32.
34. Gibson P, 2005. How to start an ACE inhibitor. [online]. Available: http://renux.dmed.ed.ac.uk/EdREN/Unitbits/ACEIstart.html [Accessed 16 November 2006].
35. Nephrology Pharmacy Associates, 2004. Kidney Disease 04. A Handbook of clinical practice guidelines [online]. Available: http://www.nephrologypharmacy.com/downloads/KidneyDisease.pdf [Accessed 16 November 2006].
36. Casas JP et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366: 2026-33.
37. Glucophage. Summary of product characteristics, UK. Merck Pharmaceuticals, October 2004.
38. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
39. Salpeter S et al. Risk of fatal and non-fatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2006, Issue 1.Art No.: CD002967. DOI: 10.1002/ 14651858.CD002967.pub2.
40. Avandia. Summary of product characteristics, UK. GlaxoSmithKline, August 2006.
41. Wong TY et al. Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 2005; 46: 713-9.
42. Hulot JS et al. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther 2005; 77: 542-52.
43. Lim W et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144: 673-84.
44. Stacul F et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol 2006; 98 (suppl): 59-77.